Skip to main content

Research Repository

Advanced Search

Polygenic architecture informs potential vulnerability to drug-induced liver injury

Koido, Masaru; Kawakami, Eri; Fukumura, Junko; Noguchi, Yui; Ohori, Momoko; Nio, Yasunori; Nicoletti, Paola; Aithal, Guruprasad P.; Daly, Ann K.; Watkins, Paul B.; Anayama, Hisashi; Dragan, Yvonne; Shinozawa, Tadahiro; Takebe, Takanori

Polygenic architecture informs potential vulnerability to drug-induced liver injury Thumbnail


Authors

Masaru Koido

Eri Kawakami

Junko Fukumura

Yui Noguchi

Momoko Ohori

Yasunori Nio

Paola Nicoletti

Ann K. Daly

Paul B. Watkins

Hisashi Anayama

Yvonne Dragan

Tadahiro Shinozawa

Takanori Takebe



Abstract

Drug-Induced-Liver-Injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market, and this is partially due to the inability to identify patients who are at risk1. Here, we developed a polygenic risk score (PRS) for DILI by aggregating effects of numerous genome-wide loci identified from previous large-scale genome-wide association studies (GWAS)2. The PRS predicted the susceptibility to DILI in patients treated with fasiglifam, amoxicillin-clavulanate or flucloxacillin, and in primary hepatocytes and stem cell-derived organoids from multiple donors treated with over 10 different drugs. Pathway analysis highlighted processes previously implicated in DILI, including unfolded protein responses and oxidative stress. In silico screening identified compounds that elicit transcriptomic signatures present in hepatocytes from individuals with elevated PRS, supporting mechanistic links and suggesting a novel screen for safety of new drug candidates. This genetic-, cellular-, organoid- and human-scale evidence underscored the polygenic architecture underlying DILI vulnerability at the level of hepatocytes, thus facilitating future mechanistic studies. Moreover, the proposed “polygenicity-in-a-dish” strategy might potentially inform designs of safer, more efficient, and robust clinical trials.

Citation

Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., Anayama, H., Dragan, Y., Shinozawa, T., & Takebe, T. (2020). Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nature Medicine, 26, 1541–1548. https://doi.org/10.1038/s41591-020-1023-0

Journal Article Type Article
Acceptance Date Jul 20, 2020
Online Publication Date Sep 7, 2020
Publication Date Sep 7, 2020
Deposit Date Jul 21, 2020
Publicly Available Date Mar 8, 2021
Journal Nature Medicine
Print ISSN 1078-8956
Electronic ISSN 1546-170X
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 26
Pages 1541–1548
DOI https://doi.org/10.1038/s41591-020-1023-0
Public URL https://nottingham-repository.worktribe.com/output/4780325
Publisher URL https://www.nature.com/articles/s41591-020-1023-0

Files





You might also like



Downloadable Citations